BCL2 is upregulated in 40–60% of patients and is associated with worse outcomes only in certain subtypes of DLBCL, while data about Ki-67 were controversial27, necessitating the identification of new predictive markers. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.